Comprehensive characterization of Rv0678 bedaquiline resistance-conferring polymorphisms
- Institution
- UNIVERSITY OF CALIFORNIA, SAN FRANCISCO, CA
- Principal investigator
- John Zapata Metcalfe
- Funding
- $246K
- Duration
- 2024–2026
Moonbase score
Still being scored
Abstract
ABSTRACT Bedaquiline is central to nearly all shorter, modernized all-oral regimens being evaluated and is revolutionizing rifampin-resistant tuberculosis treatment. Yet, despite extensive research activity in this space, a poor understanding of the genotype-phenotype correlation (i.e., the association between specific mutations (genotype) and the resulting spectrum of resistance) is the primary barrier to developing an accurate molecular diagnostic for bedaquiline. We propose accelerating discovery in this area using an unbiased, comprehensive mutational and screening strategy to determine the range and scope of all rv0678 mutations conferring bedaquiline resistance. We will construct a library of M. tuberculosis clones carrying single-nucleotide polymorphisms and specific indels, and we will screen this library in vitro and in a murine model. The success of our proposed work will provide a template to accelerate the discovery of resistance-conferring variants for all new and repurposed agents and help close the diagnostic gap, allowing for the development of tests to rapidly inform treatment decisions, regardless of resource setting.
LOADING MOONBASE SCORE
Questions for UNIVERSITY OF CALIFORNIA, SAN FRANCISCO
Answered by the team behind this research.
No questions yet. Sign in to ask the first one
Related grants
Same researchers, same institution, same topic, scored first.
- NIH · University of California, San FranciscoNot yet scored
Handheld and population-based sequencing for rapid detection of new and repurposed drug resistance in M. tuberculosis
David M Engelthaler · $291K · 2025–2027
- NIH · University of California, San FranciscoNot yet scored
A novel cartridge-based sequencing solution for decentralized M. tuberculosis resistance detection
Soumitesh Chakravorty · $700K · 2023–2028
- NIH · University of California, San FranciscoNot yet scored
Handheld and population-based sequencing for rapid detection of new and repurposed drug resistance in M. tuberculosis
David M Engelthaler · $414K · 2021–2027